SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of May 2014
FRESENIUS MEDICAL CARE AG & Co. KGaA
(Translation of registrants name into English)
Else-Kröner Strasse 1
61346 Bad Homburg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82
On May 15, 2014 Fresenius Medical Care AG & Co. KGaA (the Company) issued a Press Release announcing that the Company confirmed its long-term growth targets and that the shareholders approved the 17th consecutive dividend increase.
EXHIBITS
Exhibit 99.1 |
Press Release issued May 15, 2014. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DATE: May 15, 2014 |
| |||
|
| |||
|
FRESENIUS MEDICAL CARE AG & Co. KGaA, | |||
|
a partnership limited by shares, represented by: | |||
|
| |||
|
FRESENIUS MEDICAL CARE MANAGEMENT AG, its | |||
|
general partner | |||
|
| |||
|
| |||
|
|
By: |
/s/ RICE POWELL | |
|
|
|
| |
|
|
Name: |
Rice Powell | |
|
|
|
| |
|
|
Title: |
Chief Executive Officer and | |
|
|
|
Chairman of the Management Board | |
|
|
|
of the General Partner | |
|
| |||
|
| |||
|
By: |
/s/ MICHAEL BROSNAN | ||
|
|
| ||
|
|
Name: |
Michael Brosnan | |
|
|
|
| |
|
|
Title: |
Chief Financial Officer and | |
|
|
Member of the Management Board | ||
|
|
of the General Partner | ||
Exhibit 99.1
Press Release |
Matthias Link |
|
Corporate Communications |
|
|
|
Fresenius Medical Care |
|
Else-Kröner-Straße 1 |
|
61352 Bad Homburg |
|
Germany |
|
T +49 6172 609-2872 |
|
F +49 6172 609-2294 |
|
matthias.link@fresenius.com |
|
www.fmc-ag.com |
May 15, 2014
Fresenius Medical Care confirms long-term growth targets -
Shareholders approve 17th consecutive dividend increase
Fresenius Medical Care, the worlds largest provider of dialysis products and services, expects continued strong growth in the coming years. At todays Annual General Meeting in Frankfurt, Rice Powell, chief executive officer, confirmed the long-term targets announced in April. The company expects sales to almost double to about $28 billion in 2020 from $14.6 billion last year. This represents a cumulative average growth rate (CAGR) of about 10 percent annually between 2015 and 2020, with high-single-digit increases in net income and earnings per share over the same period.
These are ambitious targets no question, Rice Powell said in his speech to shareholders. But with our unwavering focus on growth and efficiency, I am certain that we will meet the companys long-term goals. We are the global leaders in dialysis, and our company is continuing to shape the future of the dialysis industry. By expanding into dialysis-related medical services we will be able to better coordinate care, to the benefit of all our patients.
Rice Powell also confirmed the companys guidance for 2014. Fresenius Medical Care expects revenue to be at around $15.2 billion, translating into a growth rate of around 4%. Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be between $1.0 billion and $1.05 billion in 2014.
With a large majority of 99.85%, shareholders approved Fresenius Medical Cares 17th consecutive dividend increase. The dividend will be raised to 0.77 from 0.75 per ordinary share.
A shareholder majority of over 99% approved the actions of both the Management and Supervisory Boards in 2013.
At the annual general meeting, 74.28% of the subscribed capital was represented.
Fresenius Medical Care is the worlds largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.5 million individuals worldwide. Through its network of 3,263 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 270,570 patients around the globe. Fresenius Medical Care is also the worlds leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
For more information about Fresenius Medical Care, visit the Companys website at www.fmc-ag.com.
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaAs reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.